Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
IFITMs are broad antiviral factors that block incoming virions in endosomal vesicles, protecting target cells from infection. In the case of HIV-1, we and others reported the existence of an additional antiviral mechanism through which IFITMs lead to the production of virions of reduced infectivity. However, whether this second mechanism of inhibition is unique to HIV or extends to other viruses is currently unknown. To address this question, we have analyzed the susceptibility of a broad spectrum of viruses to the negative imprinting of the virion particles infectivity by IFITMs. The results we have gathered indicate that this second antiviral property of IFITMs extends well beyond HIV and we were able to identify viruses susceptible to the three IFITMs altogether (HIV-1, SIV, MLV, MPMV, VSV, MeV, EBOV, WNV), as well as viruses that displayed a member-specific susceptibility (EBV, DUGV), or were resistant to all IFITMs (HCV, RVFV, MOPV, AAV). The swapping of genetic elements between resistant and susceptible viruses allowed us to point to specificities in the viral mode of assembly, rather than glycoproteins as dominant factors of susceptibility. However, we also show that, contrarily to X4-, R5-tropic HIV-1 envelopes confer resistance against IFITM3, suggesting that viral receptors add an additional layer of complexity in the IFITMs-HIV interplay. Lastly, we show that the overall antiviral effects ascribed to IFITMs during spreading infections, are the result of a bimodal inhibition in which IFITMs act both by protecting target cells from incoming viruses and in driving the production of virions of reduced infectivity. Overall, our study reports for the first time that the negative imprinting of the virion particles infectivity is a conserved antiviral property of IFITMs and establishes IFITMs as a paradigm of restriction factor capable of interfering with two distinct phases of a virus life cycle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IFITM proteins are broad antiviral factors that inhibit viral entry and exit for HIV-1, SIV, MLV, VSV, EBOV, WNV, among other viruses69.”
From HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages (2024) · cites this paper as [69]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,433
Keele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,912
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx
Laguette, N., Sobhian, B., Casartelli, N., Ringeard, M., Chable-Bessia, C., Ségéral, E., Yatim, A., Emiliani, S., Schwartz, O., & Benkirane, M. (2011) · Nature · doi:10.1038/nature10117 · Cited by 1,511 · cited 1×
“This trick allows a very efficient transduction of myeloid cells by HIV-1 [88] [89] [90] thanks to the reported ability of Vpx to remove the restriction factor SAMHD1 [91, 92] .”
BackgroundTsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding
Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Côté, M., Rich, R. L., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00506-2 · Cited by 1,369 · cited 1×
“These results are intriguing because MLV and especially MPMV display assembly specificities that are distinct from lentiviruses, although they ultimately acquire a plasma membrane-derived envelope [56, 57, 58] .”
ResultBrass, A. L., Huang, I.-C., Benita, Y., John, S. P., Krishnan, M. N., Feeley, E. M., Ryan, B. J., Weyer, J. L., van der Weyden, L., Fikrig, E., et al. (2009) · Cell · doi:10.1016/j.cell.2009.12.017 · Cited by 1,269
Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein
Hrecka, K., Hao, C., Gierszewska, M., Swanson, S. K., Kesik-Brodacka, M., Srivastava, S., Florens, L., Washburn, M. P., & Skowronski, J. (2011) · Nature · doi:10.1038/nature10195 · Cited by 1,200 · cited 1×
“This trick allows a very efficient transduction of myeloid cells by HIV-1 [88] [89] [90] thanks to the reported ability of Vpx to remove the restriction factor SAMHD1 [91, 92] .”
BackgroundInfectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes
Bartosch, B., Dubuisson, J., & Cosset, F.-L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021756 · Cited by 1,111
IFITM3 restricts the morbidity and mortality associated with influenza
The GenISIS Investigators, Everitt, A. R., The MOSAIC Investigators, Clare, S., Pertel, T., John, S. P., Wash, R. S., Smith, S. E., Chin, C. R., Feeley, E. M., et al. (2012) · Nature · doi:10.1038/nature10921 · Cited by 782
Friedman, R. L., Manly, S. P., McMahon, M., Kerr, I. M., & Stark, G. R. (1984) · Cell · doi:10.1016/0092-8674(84)90270-8 · Cited by 718
HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes
Miyauchi, K., Kim, Y., Latinovic, O., Morozov, V., & Melikyan, G. B. (2009) · Cell · doi:10.1016/j.cell.2009.02.046 · Cited by 681
Huang, I.-C., Bailey, C. C., Weyer, J. L., Radoshitzky, S. R., Becker, M. M., Chiang, J. J., Brass, A. L., Ahmed, A. A., Chi, X., Dong, L., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001258 · Cited by 603
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon
Kato, T., Date, T., Miyamoto, M., Furusaka, A., Tokushige, K., Mizokami, M., & Wakita, T. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.023 · Cited by 590
Dreux, M., Garaigorta, U., Boyd, B., Décembre, E., Chung, J., Whitten-Bauer, C., Wieland, S., & Chisari, F. V. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.08.010 · Cited by 475
Self-citationThe IFITM Proteins Inhibit HIV-1 Infection
Lu, J., Pan, Q., Rong, L., Liu, S.-L., & Liang, C. (2011) · Journal of Virology · doi:10.1128/jvi.01531-10 · Cited by 417
Palmitoylome profiling reveals S-palmitoylation–dependent antiviral activity of IFITM3
Yount, J. S., Moltedo, B., Yang, Y.-Y., Charron, G., Moran, T. M., López, C. B., & Hang, H. C. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.405 · Cited by 367
IFITM Proteins Restrict Viral Membrane Hemifusion
Li, K., Markosyan, R. M., Zheng, Y.-M., Golfetto, O., Bungart, B., Li, M., Ding, S., He, Y., Liang, C., Lee, J. C., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003124 · Cited by 358
The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry
Amini-Bavil-Olyaee, S., Choi, Y. J., Lee, J. H., Shi, M., Huang, I.-C., Farzan, M., & Jung, J. U. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.03.006 · Cited by 348
Grimm, D., Kay, M. A., & Kleinschmidt, J. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00095-9 · Cited by 344 · cited 1×
“• AAV-derived viral particles [77] were also produced by co-transfection of DNAs coding for IFITMs as well as for the AAV Rep proteins and cognate gfp-bearing genome at a ratio of 12:8:4, respectively.”
BackgroundDesai, T. M., Marin, M., Chin, C. R., Savidis, G., Brass, A. L., & Melikyan, G. B. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004048 · Cited by 326
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection
Freed, E. O., Englund, G., & Martin, M. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3949-3954.1995 · Cited by 300
Weidner, J. M., Jiang, D., Pan, X.-B., Chang, J., Block, T. M., & Guo, J.-T. (2010) · Journal of Virology · doi:10.1128/jvi.01328-10 · Cited by 285
Mutagen-directed Attenuation of Rift Valley Fever Virus as a Method for Vaccine Development
Caplen, H., Peters, C. J., & Bishop, D. H. L. (1985) · Journal of General Virology · doi:10.1099/0022-1317-66-10-2271 · Cited by 283
Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273 · cited 1×
“Antibodies were either acquired, or provided as described in the Supplementary S2 Table and in the following references [68] [69] [70] [71] .”
BackgroundPersistent Hepatitis C Virus Infection In Vitro: Coevolution of Virus andHost
Zhong, J., Gastaminza, P., Chung, J., Stamataki, Z., Isogawa, M., Cheng, G., McKeating, J. A., & Chisari, F. V. (2006) · Journal of Virology · doi:10.1128/jvi.01307-06 · Cited by 253
IFITMs Restrict the Replication of Multiple Pathogenic Viruses
Perreira, J. M., Chin, C. R., Feeley, E. M., & Brass, A. L. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.09.024 · Cited by 232
IFITM Proteins Incorporated into HIV-1 Virions Impair Viral Fusion and Spread
Compton, A. A., Bruel, T., Porrot, F., Mallet, A., Sachse, M., Euvrard, M., Liang, C., Casartelli, N., & Schwartz, O. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.11.001 · Cited by 231 · cited 5×
“On the contrary, the existence of an additional mechanism of viral interference with which IFITMs could lead to the formation of virions of reduced infectivity had been previously reported only in the case of HIV-1 [18, 19, 22] .”
BackgroundInfluentialIfitm3 Limits the Severity of Acute Influenza in Mice
Bailey, C. C., Huang, I.-C., Kam, C., & Farzan, M. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002909 · Cited by 231
The IFITMs Inhibit Zika Virus Replication
Savidis, G., Perreira, J. M., Portmann, J. M., Meraner, P., Guo, Z., Green, S., & Brass, A. L. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.074 · Cited by 231
Glaser, R., Zhang, H. Y., Yao, K. T., Zhu, H. C., Wang, F. X., Li, G. Y., Wen, D. S., & Li, Y. P. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9524 · Cited by 212
Goujon, C., Rivière, L., Jarrosson-Wuilleme, L., Bernaud, J., Rigal, D., Darlix, J.-L., & Cimarelli, A. (2007) · Retrovirology · doi:10.1186/1742-4690-4-2 · Cited by 205
Self-citation[26] Generation of HIV-1 derived lentiviral vectors
Follenzi, A., & Naldini, L. (2002) · Methods in Enzymology · doi:10.1016/s0076-6879(02)46071-5 · Cited by 199
Interferon induction of IFITM proteins promotes infection by human coronavirus OC43
Zhao, X., Guo, F., Liu, F., Cuconati, A., Chang, J., Block, T. M., & Guo, J.-T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320856111 · Cited by 191
John, S. P., Chin, C. R., Perreira, J. M., Feeley, E. M., Aker, A. M., Savidis, G., Smith, S. E., Elia, A. E. H., Everitt, A. R., Vora, M., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00481-13 · Cited by 182
Narayana, S. K., Helbig, K. J., McCartney, E. M., Eyre, N. S., Bull, R. A., Eltahla, A., Lloyd, A. R., & Beard, M. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657346 · Cited by 181
Jia, R., Pan, Q., Ding, S., Rong, L., Liu, S.-L., Geng, Y., Qiao, W., & Liang, C. (2012) · Journal of Virology · doi:10.1128/jvi.01828-12 · Cited by 181
Zeisel, M. B., Felmlee, D. J., & Baumert, T. F. (2013) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-27340-7_4 · Cited by 179
Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction
Foster, T. L., Wilson, H., Iyer, S. S., Coss, K., Doores, K., Smith, S., Kellam, P., Finzi, A., Borrow, P., Hahn, B. H., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.08.006 · Cited by 171
IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein
Yu, J., Li, M., Wilkins, J., Ding, S., Swartz, T. H., Esposito, A. M., Zheng, Y.-M., Freed, E. O., Liang, C., Chen, B. K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.055 · Cited by 170
Human ESCRT-II Complex and Its Role in Human Immunodeficiency Virus Type 1 Release
Langelier, C., von Schwedler, U. K., Fisher, R. D., De Domenico, I., White, P. L., Hill, C. P., Kaplan, J., Ward, D., & Sundquist, W. I. (2006) · Journal of Virology · doi:10.1128/jvi.01049-06 · Cited by 166
Rhee, S. S., & Hunter, E. (1990) · Cell · doi:10.1016/0092-8674(90)90289-q · Cited by 160
Fusion from without directed by human immunodeficiency virus particles
Clavel, F., & Charneau, P. (1994) · Journal of Virology · doi:10.1128/jvi.68.2.1179-1185.1994 · Cited by 159
Goujon, C., Jarrosson, L., Bernaud, J., Rigal, D., Darlix, J. L., & Cimarelli, A. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302753 · Cited by 157
Self-citationWrensch, F., Winkler, M., & Pöhlmann, S. (2014) · Viruses · doi:10.3390/v6093683 · Cited by 147
Strobel, B., Miller, F. D., Rist, W., & Lamla, T. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.051 · Cited by 146
Chesarino, N. M., McMichael, T. M., Hach, J. C., & Yount, J. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.557694 · Cited by 140
IFITM-2 and IFITM-3 but Not IFITM-1 Restrict Rift Valley Fever Virus
Mudhasani, R., Tran, J. P., Retterer, C. J., Radoshitzky, S. R., Kota, K. P., Altamura, L. A., Smith, J. M., Packard, B. Z., Kuhn, J. H., Costantino, J. A., et al. (2013) · Journal of Virology · doi:10.1128/jvi.03382-12 · Cited by 139
IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity
Tartour, K., Appourchaux, R., Gaillard, J., Nguyen, X.-N., Durand, S., Turpin, J., Beaumont, E., Roch, E., Berger, G., Mahieux, R., et al. (2014) · Retrovirology · doi:10.1186/s12977-014-0103-y · Cited by 139
Self-citationWulff, H., McIntosh, B. M., Hamner, D. B., & Johnson, K. M. (1977) · Europe PMC (PubMed Central) · Cited by 137
Berlioz, C., & Darlix, J. L. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2214-2222.1995 · Cited by 137
Zhu, X., He, Z., Yuan, J. X., Wen, W., Huang, X., Hu, Y., Lin, C., Pan, J., Li, R., Deng, H., et al. (2014) · Cellular Microbiology · doi:10.1111/cmi.12339 · Cited by 134
Jia, R., Xu, F., Qian, J., Yao, Y., Miao, C., Zheng, Y.-M., Liu, S.-L., Guo, F., Geng, Y., Qiao, W., et al. (2014) · Cellular Microbiology · doi:10.1111/cmi.12262 · Cited by 133
Interferon-inducible Transmembrane Protein 3 (IFITM3) Restricts Reovirus Cell Entry
Anafu, A. A., Bowen, C. H., Chin, C. R., Brass, A. L., & Holm, G. H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438515 · Cited by 129
Amphotericin B Increases Influenza A Virus Infection by Preventing IFITM3-Mediated Restriction
Lin, T.-Y., Chin, C. R., Everitt, A. R., Clare, S., Perreira, J. M., Savidis, G., Aker, A. M., John, S. P., Sarlah, D., Carreira, E. M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.033 · Cited by 123
Cell entry of enveloped viruses
Plemper, R. K. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.06.002 · Cited by 122
Interferon-induced Transmembrane Protein 3 Is a Type II Transmembrane Protein
Bailey, C. C., Kondur, H. R., Huang, I., & Farzan, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.514356 · Cited by 119
High Levels of Transduction of Human Dendritic Cells with Optimized SIV Vectors
Mangeot, P.-E., Duperrier, K., Nègre, D., Boson, B., Rigal, D., Cosset, F.-L., & Darlix, J.-L. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0541 · Cited by 117
Gruffat, H., Manet, E., & Sergeant, A. (2002) · EMBO reports · doi:10.1093/embo-reports/kvf031 · Cited by 114
Self-citationAn infectious West Nile Virus that expresses a GFP reporter gene
Pierson, T. C., Diamond, M., Ahmed, A. A., Valentine, L. E., Davis, C. W., Samuel, M. A., Hanna, S. L., Puffer, B. A., & Doms, R. W. (2005) · Virology · doi:10.1016/j.virol.2005.01.021 · Cited by 114
Poddar, S., Hyde, J., Gorman, M. J., Farzan, M., & Diamond, M. (2016) · Journal of Virology · doi:10.1128/jvi.00655-16 · Cited by 113
Berger, G., Durand, S., Goujon, C., Nguyen, X.-N., Cordeil, S., Darlix, J., & Cimarelli, A. (2011) · Nature Protocols · doi:10.1038/nprot.2011.327 · Cited by 108
Self-citationNatural mutations in IFITM3 modulate post‐translational regulation and toggle antiviral specificity
Compton, A. A., Roy, N., Porrot, F., Billet, A., Casartelli, N., Yount, J. S., Liang, C., & Schwartz, O. (2016) · EMBO Reports · doi:10.15252/embr.201642771 · Cited by 107
Ebolavirus Glycoprotein GP Masks both Its Own Epitopes and the Presence of Cellular Surface Proteins
Reynard, O., Borowiak, M., Volchkova, V. A., Delpeut, S., Mateo, M., & Volchkov, V. E. (2009) · Journal of Virology · doi:10.1128/jvi.00784-09 · Cited by 97
Self-citationDefining the Range of Pathogens Susceptible to Ifitm3 Restriction Using a Knockout Mouse Model
Everitt, A. R., Clare, S., McDonald, J. U., Kane, L., Harcourt, K., Ahras, M., Lall, A., Hale, C., Rodgers, A., Young, D. B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080723 · Cited by 96
The Interferon-Stimulated Gene Ifitm3 Restricts West Nile Virus Infection and Pathogenesis
Gorman, M. J., Poddar, S., Farzan, M., & Diamond, M. (2016) · Journal of Virology · doi:10.1128/jvi.00581-16 · Cited by 95
A Membrane Topology Model for Human Interferon Inducible Transmembrane Protein 1
Weston, S., Czieso, S., White, I. J., Smith, S. E., Kellam, P., & Marsh, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104341 · Cited by 89
Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes
Hanika, A., Larisch, B., Steinmann, E., Schwegmann-Weßels, C., Herrler, G., & Zimmer, G. (2005) · Journal of General Virology · doi:10.1099/vir.0.80788-0 · Cited by 85
Farber, C. R., Reich, A., Barnes, A. M., Becerra, P., Rauch, F., Cabral, W. A., Bae, A., Quinlan, A., Glorieux, F. H., Clemens, T. L., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2173 · Cited by 83
Devaux, P., & Cattaneo, R. (2004) · Journal of Virology · doi:10.1128/jvi.78.21.11632-11640.2004 · Cited by 83
Role of Ebola Virus VP30 in Transcription Reinitiation
Martínez, M. J., Biedenkopf, N., Volchkova, V., Hartlieb, B., Alazard-Dany, N., Reynard, O., Becker, S., & Volchkov, V. (2008) · Journal of Virology · doi:10.1128/jvi.01395-08 · Cited by 83
Self-citationGiraudon, P., Jacquier, M. F., & Wild, T. (1988) · Virus Research · doi:10.1016/0168-1702(88)90011-1 · Cited by 80
Warren, C. J., Griffin, L., Little, A. S., Huang, I., Farzan, M., & Pyeon, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096579 · Cited by 79
ZMPSTE24 defends against influenza and other pathogenic viruses
Fu, B., Wang, L., Li, S., & Dorf, M. E. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161270 · Cited by 78
Antiviral Role of IFITM Proteins in African Swine Fever Virus Infection
Muñoz-Moreno, R., Cuesta-Geijo, M. Á., Martínez‐Romero, C., Barrado-Gil, L., Galindo, I., García‐Sastre, A., & Alonso, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154366 · Cited by 74
Gerlach, T. H., Hensen, L., Matrosovich, T. Y., Bergmann, J., Winkler, M., Peteranderl, C., Klenk, H., Weber, F., Herold, S., Pöhlmann, S., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00246-17 · Cited by 69
Xie, M., Xuan, B., Shan, J., Pan, D. Y., Sun, Y., Zhao, S., Zhang, J., Yu, D. L., Li, B., & Qian, Z. (2015) · Journal of Virology · doi:10.1128/jvi.03416-14 · Cited by 65
Intermediate conformations during viral fusion glycoprotein structural transition
Baquero, E., Albertini, A., Vachette, P., Lepault, J., Bressanelli, S., & Gaudin, Y. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.03.006 · Cited by 56
The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity
Wang, Y., Pan, Q., Ding, S., Wang, Z., Yu, J., Finzi, A., Liu, S.-L., & Liang, C. (2017) · Journal of Virology · doi:10.1128/jvi.02441-16 · Cited by 56
Transduction of Nondividing Human Macrophages with Gammaretrovirus-Derived Vectors
Jarrosson-Wuilleme, L., Goujon, C., Bernaud, J., Rigal, D., Darlix, J.-L., & Cimarelli, A. (2006) · Journal of Virology · doi:10.1128/jvi.80.3.1152-1159.2006 · Cited by 52
Self-citationOtt, D. E. (2008) · Methods in Molecular Biology · doi:10.1007/978-1-59745-170-3_2 · Cited by 49
Studying HCV Cell Entry with HCV Pseudoparticles (HCVpp)
Bartosch, B., & Cosset, F. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-394-3_21 · Cited by 48
Human respiratory syncytial virus infection is inhibited by IFN-induced transmembrane proteins
Zhang, W., Zhang, L., Zan, Y., Du, N., Yang, Y., & Tien, P. (2014) · Journal of General Virology · doi:10.1099/vir.0.066555-0 · Cited by 48
Alphavirus Restriction by IFITM Proteins
Weston, S. M., Czieso, S., White, I. J., Smith, S. E., Wash, R. S., Soria, C. L. D., Kellam, P., & Marsh, M. (2016) · Traffic · doi:10.1111/tra.12416 · Cited by 46
HIV-1 mutates to evade IFITM1 restriction
Ding, S., Pan, Q., Liu, S., & Liang, C. (2014) · Virology · doi:10.1016/j.virol.2014.01.020 · Cited by 44
Primate lentiviruses are differentially inhibited by interferon-induced transmembrane proteins
Qian, J., Duff, Y. L., Wang, Y., Pan, Q., Ding, S., Zheng, Y.-M., Liu, S., & Liang, C. (2014) · Virology · doi:10.1016/j.virol.2014.10.015 · Cited by 40
Δ20 IFITM2 differentially restricts X4 and R5 HIV-1
Wu, W., Grotefend, C. R., Tsai, M.-T., Wang, Y., Radic, V., Eoh, H., & Huang, I. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619640114 · Cited by 39
Kasaai, B., Gaumond, M.-H., & Moffatt, P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.457010 · Cited by 32
Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV
Wilkins, J. M., Zheng, Y.-M., Yu, J., Liang, C., & Liu, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156739 · Cited by 31
Desai, T. M., Marin, M., Mason, C. S., & Melikyan, G. B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.783878 · Cited by 27
Tatsuo, H., Ono, N., Tanaka, K., & Yanagi, Y. (2000) · Uirusu · doi:10.2222/jsv.50.289 · Cited by 17
Dugbe Nairovirus S Segment: Correction of Published Sequence and Comparison of Five Isolates
Bridgen, A., Dalrymple, D. A., & Elliott, R. M. (2002) · Virology · doi:10.1006/viro.2001.1324 · Cited by 13
Wrensch, F., Hoffmann, M., Gärtner, S., Nehlmeier, I., Winkler, M., & Pöhlmann, S. (2016) · Journal of Virology · doi:10.1128/jvi.01488-16 · Cited by 13
Postentry Restriction of Mason-Pfizer Monkey Virus in Mouse Cells
Wang, G. Z., & Goff, S. P. (2014) · Journal of Virology · doi:10.1128/jvi.03051-14 · Cited by 11
Ostertag, D. G., Hoblitzell-Ostertag, T. M., & Perrault, J. (2006) · Journal of Virology · doi:10.1128/jvi.01217-06 · Cited by 11
Research works printed but not linked: 3
- R Jia, 2014, Identification of an endocytic signal essential for the antiviral action of IFITM3, Cell Microbiol
- NM Chesarino, 2014, Phosphorylation of the Antiviral Protein IFITM3 Dually Regulates its Endocytosis and Ubiquitination, J Biol Chem
- X Zhu, 2014, IFITM3-containing exosome as a novel mediator for anti-viral response in dengue virus infection, Cell Microbiol
Cited by
IFITM Genes, Variants, and Their Roles in the Control and Pathogenesis of Viral Infections
Zhao, X., Li, J., Winkler, C. A., An, P., & Guo, J. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03228 · Cited by 164
IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity
Gómez-Herranz, M., Taylor, J., & Sloan, R. D. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102741 · Cited by 131
Shi, G., Schwartz, O., & Compton, A. A. (2017) · Retrovirology · doi:10.1186/s12977-017-0377-y · Cited by 109
Chemudupati, M., Kenney, A. D., Bonifati, S., Zani, A., McMichael, T. M., Wu, L. J., & Yount, J. S. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.09.012 · Cited by 102
Guo, X., Steinkühler, J., Marin, M., Li, X., Lu, W., Dimova, R., & Melikyan, G. B. (2021) · ACS Nano · doi:10.1021/acsnano.0c10567 · Cited by 96
Metadata
- Authors
- Tartour, K., Nguyen, X.-N., Appourchaux, R., Assil, S., Barateau, V., Bloyet, L.-M., Burlaud Gaillard, J., Confort, M.-P., Escudero-Perez, B., Gruffat, H., Hong, S. S., Moroso, M., Reynard, O., Reynard, S., Decembre, E., Ftaich, N., Rossi, A., Wu, N., Arnaud, F., Baize, S., Dreux, M., Gerlier, D., Paranhos-Baccala, G., Volchkov, V., Roingeard, P., & Cimarelli, A.
- Affiliations
- Lyon 1 Université (FR)
- Université de Tours (FR)
- Corresponding author
- Cimarelli, Andrea
- ORCID
- Assil, Sonia
- Barateau, Véronique
- Bloyet, Louis-Marie
- Confort, Marie-Pierre
- Gruffat, Henri
- Hong, Saw See
- Moroso, Marie
- Reynard, Olivier
- Reynard, Stéphanie
- Rossi, Axel
- Wu, Nannan
- Arnaud, Frédérick
- Baize, Sylvain
- Dreux, Marlène
- Gerlier, Denis
- Paranhos-Baccala, Glaucia
- Volchkov, Viktor
- Roingeard, Philippe
- Cimarelli, Andrea
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-09-28
- Volume
- 13
- Issue
- 9
- Pages
- e1006610
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC5619827
- OpenAlex
- W2759331290
- Cited by
- 69
- References
- 93
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 10 · 2023: 6 · 2022: 5 · 2021: 14 · 2020: 8 · 2019: 7 · 2018: 10 · 2017: 1
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Fondation Innovations en Infectiologie
- Sidaction
- Agence Nationale de la Recherche (ANR-14-EBOL-0002)
- Deutsches Primatenzentrum
- Institut National de la Recherche Agronomique
- Université de Lyon
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- interferon-induced transmembrane proteins, IFITM3, HIV-1, viral infectivity, viral assembly, host restriction factors, viral receptor, viral replication inhibition, broad-spectrum antiviral activity
- MeSH terms
- Antigens, Differentiation, Cell Line, Humans, Virion, Virus Replication, HIV-1, Virus Internalization, Host-Pathogen Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.